NCT02106494View on ClinicalTrials.gov

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

PHASE3CompletedINTERVENTIONAL
Enrollment

942

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
DRUG

APF530

DRUG

Ondansetron

DRUG

Ondansetron placebo

DRUG

APF530 placebo

DRUG

Fosaprepitant

DRUG

Dexamethasone

Trial Locations (7)

11733

North Shore Oncology, East Setauket

44718

Gabrail Cancer Center Research, Canton

46545

Northern Indiana Research, Mishawaka

46804

Northern Indiana Research, South Bend

85016

Arizona Oncology Associates, PC-HAL, Pheonix

90241

The Oncology Institute of Hope and Innovation, Downey

92501

Compassionate Cancer Medical Center, Riverside

Sponsors

Lead Sponsor

Heron Therapeutics
All Listed Sponsors
lead

Heron Therapeutics

INDUSTRY